Latest news with #IVI
Yahoo
6 days ago
- Automotive
- Yahoo
How software is shaping the future of mobility
The automotive industry is undergoing one of the most significant transformations in over a century – driven not by hardware, but by software. Vehicles will be digitized and increasingly defined by the compute architecture and software that powers their functionality and intelligence. The rise of the Software-Defined Vehicle (SDV) is changing how cars are designed, built, and experienced, but to realize those benefits, automakers, T1s, software, and semiconductor vendors must evolve. Switch Auto Insurance and Save Today! Great Rates and Award-Winning Service The Insurance Savings You Expect Affordable Auto Insurance, Customized for You The digitization of the car Before we look at how the industry needs to adapt, it's worth taking a step back and considering what we mean by SDVs. These aren't just vehicles that are developed, built, and sold, but vehicles which evolve and improve after they've left the production line based on a dynamic digital platform. This transformation is about redefining the vehicle's core architecture and how it is experienced. In a software-defined vehicle, features and functions are increasingly abstracted from hardware and run in software. To achieve this, some sort of central compute architecture is required – a platform that enables continuous updates, upgrades, and even personalization of the car. This means vehicles require a powerful and scalable electronics architecture based on semiconductors (hardware), efficient and scalable software drivers and middleware to integrate all the electronics, and on top of it intelligent and feature-rich application software to define the functionality of the car. Such an SDV platform manages everything from ADAS (Advanced Driver Assistance Systems) to IVI (In-Vehicle Infotainment). Most importantly, it includes the core vehicle functions to operate and to propel the car, which becomes even more important for electric vehicles where intelligent energy flow and battery management significantly impacts the lifetime and range of the vehicle. This new approach to vehicle compute architecture makes it possible to activate new features after the car is sold, adapt vehicle behavior in real time, and evolve interfaces as technology and user preferences shift – such adaptations are prohibitively complex in traditional vehicles. SDVs therefore enable a completely new value proposition: the car gets smarter and better with age. With the rise of AI, the SDV platform only becomes more critical, with AI-powered ADAS, preventive fault detection or range optimizations, for example, transforming how we use our vehicles. Together, these shifts mark a clear departure from the traditional vehicle lifecycle defined by depreciation and eventual obsolescence. But this evolution brings complexity. Building a car that improves over time – and is ready to integrate the next-generation of AI – requires a fundamental rethinking of design, supply chains, and safety. Processes and priorities that have been in place for decades now need to evolve. Rethinking traditional architectures Traditionally, vehicle functions were tightly coupled to specific electronic control units (ECUs), each often developed by different suppliers. This hardware-centric approach meant that adding or modifying features required changes to the underlying ECU hardware and their specific software modules – making updates complex, time-consuming, and costly. Engineering teams had to navigate a patchwork of tools, processes, and dependencies, resulting in limited flexibility once the vehicle left the factory. In short, the system was rigid, expensive to maintain, and difficult to scale. The SDV concept is creating a platform that can be updated, upgraded, or personalized over time, and also enables carmakers to revolutionize how they develop and produce new vehicles. This concept allows the highest level of hardware and software re-use, which enables carmakers to develop new vehicle platforms a lot faster. Such platforms are inherently scalable. The fundamental architecture can be used across entry-level models right up to high-end models, and it can be scaled across various OEM brands. This drives speed of innovation, faster time to market, and optimizes total cost of ownership. Automakers have started making key decisions about how to evolve their compute architectures to tackle engineering challenges. Some are consolidating multiple domains into centralized compute platforms to streamline processes and reduce complexity, while others are adopting zonal architectures that distribute compute closer to the edge – near sensors and actuators – to improve latency, modularity, and scalability. Regardless of approach, meeting these demands requires more powerful semiconductors, scalable compute, greater energy efficiency, high-bandwidth communication, functional safety, the highest standards of security, and new system-level innovations. From supply chains to ecosystems This transition is also redrawing the lines of the automotive supply chain. The historical model – where automakers, Tier 1s, and semiconductor suppliers operated in a linear hierarchy – is giving way to an ecosystem of strategic collaboration. This shift is driven by the growing realization that vehicle digitization depends not only on the compute, networking, and power management technologies of a vehicle but the software that runs on it. As digital features expand, so does the complexity of integrating hardware and software efficiently across the vehicle – and no one company can do this alone. Delivering that innovation at scale calls for a new model of collaboration – one where automakers, suppliers, and technology partners work in parallel from the start. The development model behind SDVs is no longer a linear supply chain; it's a tightly integrated ecosystem. As vehicle architectures evolve to support software-defined capabilities, NXP is increasingly engaged earlier in the design process – contributing not just silicon, but system-level expertise and software solutions that helps define compute architectures. From vehicle compute and zone controllers to networking and power management, we support OEMs and Tier 1s in building safe, scalable platforms that enable long-term software innovation. Both emerging manufacturers and legacy players should play to their strengths Today's shifts in the industry are impacting automakers in very different ways. New entrants, without the burden of legacy systems, can design vehicles from the ground up with software at the center. Their streamlined product lines and software-native cultures often align more naturally with SDV architecture (as well as today's consumer preferences). However, they may face non-trivial challenges when it comes to scaling production and safety while offering a wide range of models to meet different consumer needs and expectations. Legacy OEMs and automakers, on the other hand, must manage a complex change to manufacturing processes while continuing to support existing platforms and products. Their strengths lie in deep automotive expertise, quality assurance and safety, supply chain management, and manufacturing scale. For these companies, the transition to SDVs must be carefully orchestrated and is often incremental. There's a balance to be struck for traditional manufacturers between increasing agility, playing to existing strengths, and delivering the SDV innovations that consumers increasingly demand. For both emerging and legacy manufacturers, however, several foundations will be non-negotiable: energy efficiency, robustness, cybersecurity, and functional safety to name the most critical. And each will require an increase in testing, validation, and verification across the supply chain. For electric vehicles in particular, energy efficiency is fundamental. After all, every watt consumed by processors and electronic systems is a watt not available for propulsion. Manufacturers must therefore optimize everything – from the processor architecture to power management at the ECU level – to ensure that digital performance doesn't come at the cost of driving range. Cybersecurity is equally essential. Greater digitization increases the attack surface of the vehicle. Without robust, multi-layered protections, the risk of intrusion grows. Just as homes use locks, alarms, and safes, SDVs must implement security across all domains. Cars call for the highest level of robustness and safety – the stakes are high when a software or hardware issue has the potential to put people in danger. Hardware isolation between functionalities (rather than software isolation only) is also vital for this reason. With isolation, if one function fails (or is attacked by a bad actor) failures don't spread to another. To return to the building analogy, hardware isolation acts as a series of fire doors – keeping the vehicle safe and protected even if one area is compromised. The road ahead: A smarter and safer industry As SDVs become increasingly widespread, and ADAS, IVI and core vehicle functions grow in sophistication, including anticipation and automation by AI, the auto industry is poised for profound and lasting changes. Underpinning this transformation will be a more collaborative industry – one in which legacy and emerging automakers, OEMs, and vendors work directly with one another. This will help to address the new challenges that arise and tackle them efficiently, safely, and at scale while improving time to market and total cost of ownership. It calls for all stakeholders – from semiconductor and software vendors to system integrators and vehicle manufacturers – to move beyond limited views and build an understanding of the entire system. With the industry working together in this way to build a new approach to vehicle development and functionality, significantly smarter, safer, and more secure vehicles are on the horizon. By Jens Hinrichsen, Executive Vice President and General Manager of Analog and Automotive Embedded Systems, NXP Semiconductors "How software is shaping the future of mobility" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Korea Herald
11-07-2025
- Business
- Korea Herald
Bio Investments Group (BIG) and International Vaccine Institute (IVI) Forge Partnership to Accelerate Vaccine Self-Reliance in Africa and the Middle East
ZUG, Switzerland and SEOUL, July 11, 2025 /PRNewswire/ -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International Vaccine Institute (IVI), an international organization dedicated to advancing vaccine discovery, development, and delivery, today announced the signing of a Memorandum of Understanding (MoU) to establish a strategic collaboration aimed at accelerating local vaccine manufacturing, clinical evidence generation, and capacity building across Africa and the Middle East. This partnership underscores a shared vision to enhance global health security by fostering vaccine self-reliance in emerging markets, aligning BIG's execution and investment capabilities with IVI's technical guidance and global vaccine research, development, and regulatory expertise. "This MoU marks a pivotal moment in our mission to localize life-science capabilities where they are needed most," said Sam Machour, CEO & Chairman of the Bio Investments Group. "By partnering with IVI, a globally respected institution, we are combining our investment and pharmaceutical technical capabilities in cutting-edge infrastructure and technology transfer with their deep vaccines scientific and public health expertise. Our joint efforts will accelerate the pace to self-sufficiency, will not only bring high-quality vaccines closer to African populations but also empower local economies through sustainable manufacturing and job creation." Key Areas of Cooperation under the MoU include: This collaboration is expected to significantly contribute to Africa's public health agenda by fostering a robust and resilient vaccine ecosystem, reducing reliance on imports, and strengthening regional preparedness for future health challenges. About Bio Investments Group (BIG): Bio Investments Group AG is a Swiss-registered healthcare-industrial platform dedicated to accelerating the localization of life-science capabilities, including vaccines, biologics, diagnostics, and cold-chain services, across emerging markets. With operational hubs in Zug, Hong Kong, Dubai, and Riyadh, BIG focuses on transferring technology, building infrastructure, and fostering local expertise to achieve genuine manufacturing sovereignty. About International Vaccine Institute (IVI): The International Vaccine Institute (IVI) is an international organization dedicated to advancing vaccine discovery, development, and delivery—especially for vulnerable communities. Through research, partnerships, and innovation, IVI enhances global health, strengthens pandemic preparedness, and ensures equitable access to life-saving vaccines worldwide. Logo: Media Contact:
Business Wire
14-05-2025
- Business
- Business Wire
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines
SAN DIEGO--(BUSINESS WIRE)--Today, TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, and the International Vaccine Institute (IVI), a non-profit international organization devoted to and the discovery, development and delivery of vaccines for global health signed a Memorandum of Understanding to collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies. "This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries (LMICs),' said Maravai and TriLink's Chief Commercial Officer, Becky Buzzeo. According to the terms of the MOU, TriLink and IVI will enter discussions on collaborative models to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives. "This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries (LMICs),' said Maravai and TriLink's Chief Commercial Officer, Becky Buzzeo. 'By combining our expertise in nucleic acids with the International Vaccine Institute's global reach and commitment to public health, we are poised to profoundly impact global health equity. Together, we can accelerate the development and distribution of innovative mRNA vaccines, ensuring that more people, regardless of their geographic location, have access to the critical healthcare they need." Since its launch in 2017, TriLink's CleanCap® capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In 2024, TriLink expanded its products and services specifically for customers working in mRNA therapeutics, launching IVT enzymes, including CleanScribe™ RNA polymerase, which has been shown to reduce dsRNA, and opened its commercially ready GMP manufacturing facility in San Diego, California. IVI, based in Seoul, Korea, is an autonomous international organization established in 1997 as an initiative of the United Nations Development Program. It is dedicated exclusively to vaccines for global health, with a portfolio spanning all stages of pre-clinical and clinical development. Its work focuses on infectious diseases of global health importance, particularly those that disproportionately affect LMICs, including cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, and COVID-19. 'IVI is pleased to partner with TriLink BioTechnologies, a leading provider of life science reagents and services, including its proprietary capping technology that enhances mRNA stability and translation efficiency,' said Dr. Jerome Kim, Director General of IVI. 'This collaboration will empower the two organizations and our partners to accelerate the development and global delivery of advanced mRNA vaccines, especially to people in LMICs.' About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders to enabling future pandemic response plans. For more information, visit About Maravai LifeSciences Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit About the International Vaccine Institute (IVI) The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health. IVI's current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world's first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that also achieved WHO prequalification in early 2024. IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, an Africa Regional Office in Rwanda, a Country Office in Austria, and a Country and Project Office in Kenya. IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts Collaborating Centers in Ghana, Ethiopia, and Madagascar. 42 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, Austria, and Thailand provide state funding. For more information, please visit
Time Magazine
08-05-2025
- Health
- Time Magazine
Nicaise Ndembi
More than 21,000 people in Africa contracted mpox in 2024—a bad number that could have been much worse without the help of Nicaise Ndembi, then head of the Africa Centers for Disease Control and Prevention and now the deputy director general of the International Vaccine Institute (IVI). In his time at AfricaCDC, Ndembi led the continent-wide response to mpox—strengthening surveillance and screening and providing vaccines and medicinal therapeutics—and also established the Partnerships for African Vaccine Manufacturing, which created a framework for regional vaccine manufacturing and self-reliance. In his new role at the IVI, he will work to establish home-grown vaccine research and development, accelerating vaccine availability and distribution across Africa's 54 countries.
Int'l Business Times
01-05-2025
- Business
- Int'l Business Times
How Private Investment Strategist Timi Barabas Revolutionizes Private Equity by Connecting Capital with Opportunity
Private equity has long operated behind fortress-like walls of intermediaries, gatekeepers, and protocols that add months to transactions and millions to costs. Then came activist and entrepreneur Timi Barabas, whose journey from non-English speaker to dealmaking innovator represents a fundamental challenge to this entrenched system. As senior partner and program director at Impact Ventures International (IVI), Barabas has revolutionized capital access by drastically reducing deal timelines and redefining possibilities in a traditionally rigid industry. "Most firms would take six months to make introductions happen. I just saved everyone half a year of their lives," affirms Timi Barabas . Her outlook connects investors directly with off-market investment opportunities, bypassing the lengthy process private equity investors face when sourcing deals. From Budapest Markets to Billion-Dollar Deals Timi Barabas' journey to becoming one of private equity's most innovative connectors began half a world away in Budapest, Hungary. At age 15, she immigrated to New Zealand without speaking English. Where many would see insurmountable barriers, Barabas saw only problems to solve. Within two years of arrival, despite still developing her English skills, she launched her first formal business—a caregiving and cleaning service that acquired 25 long-term clients in its first two months of operation. This pattern of turning obstacles into opportunities became her signature. By her early twenties, she had co-founded multiple businesses spanning technology, caregiving, and event management while building an extensive portfolio of non-profit work addressing causes from climate change to peace diplomacy. In 2023, she represented New Zealand at the APEC Multistakeholder Forum in San Francisco, one of only three delegates under 30 selected for this honor. Her cross-cultural fluency and growing reputation for connecting disparate worlds earned her the selection—a skill she soon applied to revolutionize private equity transactions. The Gatekeeper Problem To understand Barabas's work at IVI, one must first understand the problem she's solving. An elaborate, multi-layered system—comprising investment bankers, business brokers, consultants, and lawyers—typically governs traditional private equity deals. Each layer adds time, cost, and complexity. In the U.S. alone, the average mid-market business acquisition takes 9-12 months from initial contact to closing, with typical transaction costs often exceeding 10% of deal value. This can be a significant struggle for businesses of any size as it means thousands to millions in fees, even before launching. Moreover, this traditional system creates information asymmetry. When most deals reach potential buyers, they've been widely shopped, driving up prices and reducing potential returns. "Most investors are stuck looking at the same deals as everyone else," Barabas explains. "They waste time, money, and energy chasing opportunities already overpriced or oversaturated." Direct Access: The Barabas Method When Barabas joined Impact Ventures International in 2024, she brought a radically different perspective to deal-making. By early 2025, she had become Senior Partner of IVI and Program Director of VentureMax360, the firm's flagship program for scaling and selling mid-market companies. Her method centers on what she calls "direct market access." It connects business owners with IVI's VentureMax360 program, which focuses on growing and scaling a business to prepare for selling within a two+ year timeline. Then, Barabas connects them with potential partners and investors to create a smooth and efficient transition. This process eliminates the need to shop deals around for months and reduces delays in decision-making, thus making it easy for investors to buy functional businesses in a timely manner. "Most private equity professionals wait for deals to surface—I create them," Barabas mentions. "Traditional firms navigate layers of brokers and gatekeepers—I eliminate those delays by providing direct access to decision-makers." Her technique leverages a global relationship network that spans five continents, carefully cultivated through years of cross-cultural business development. This extensive network allows her to identify opportunities long before they become visible to traditional market participants. IVI's technology integrates CEPA-certified exit planning, VM360's scaling strategies, and IVSS Digital Office automation to identify high-potential businesses before they hit the market. What sets Barabas' method apart is her relentless focus and emphasis on speed-based execution. She acts quickly when a potential match is found, arranging discussions within days. Using AI, automation, and direct market access, she accelerates transactions far beyond traditional private equity timelines. The results speak for themselves. Barabas has worked with dozens of high-value private equity clients in the past two years, supporting private equity deal flow and client strategies in the 8-9 figure range. The Global Expansion What makes Barabas' slant particularly powerful is its global reach. While traditional private equity remains siloed mainly by geography, IVI's direct access model operates across borders. The company maintains active deal flow across Singapore, Malaysia, Africa, Canada, and the U.S., with plans to expand into Monaco and the U.K. within 12 months. "Private equity professionals often create artificial geographical barriers," Barabas says. "Capital doesn't recognize borders, and neither should deal-making." This global outlook provides another competitive advantage: cultural translation. Having navigated her own cross-cultural journey, Barabas has developed an unusual facility for bridging communication gaps that often derail international deals. The Dealmaker's Future Her direct-access model democratizes opportunity by preserving proficiency while removing unnecessary barriers in a gatekeeper-driven global economy. For Barabas, the direct-access model represents only the beginning of a more significant transformation in how capital connects with opportunity globally. Barabas' long-term vision is to scale IVI's method into "a global force for private equity matchmaking" and make way for private equity's potential future: faster, more direct, and oriented around relationships rather than institutions. "How long would it take you to get a meeting with the owner of a multi-million-dollar company willing to sell? Months? Years? Never?" she asks. "At IVI, I make those connections happen quickly and efficiently, certifying that our clients get first access to the highest-value deals—before they ever go public." The young woman who could not speak English upon arriving in New Zealand has built her career by breaking down walls between investors, entrepreneurs, and opportunities. In doing so, she's demonstrating that sometimes, the most valuable innovation is not a technology or product but a reimagining of how we connect. Private equity has always been about connecting capital with opportunity. With Impact Ventures International, Timi Barabas is turning outdated systems on their head—empowering investors with direct access and entrepreneurs with real outcomes.
